The present disclosure is directed to compositions comprising as an active ingredient, a lower dose of 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof for treating or preventing vasomotor symptoms in a subject, and methods which comprises administering the said compound or the pharmaceutically acceptable salt thereof at a lower dose, respectively.

To provide a material for improvement in a climacteric symptom such as hot flash. An oral hot flash improvement agent comprising chlorogenic acids as an active ingredient. An oral hot flash improvement agent comprising a coffee bean extract which comprises chlorogenic acids and in which a mass ratio of caffeine/chlorogenic acids is 0.015 or less, as an active ingredient.

To provide a material for improvement in a climacteric symptom such as hot flash. An oral hot flash improvement agent comprising chlorogenic acids as an active ingredient. An oral hot flash improvement agent comprising a coffee bean extract which comprises chlorogenic acids and in which a mass ratio of caffeine/chlorogenic acids is 0.015 or less, as an active ingredient.

The present disclosure relates to a composition for preventing, relieving or treating climacteric symptoms, the composition comprising lactic acid bacteria and prebiotic composition. The lactic acid bacteria of the present disclosure have β-glucosidase activity and a very excellent ability to convert isoflavones into equol compounds, and thus may exhibit estrogenic activity through synergism with the gut microbiota. Therefore, the lactic acid bacteria of the present disclosure may be effectively used for the prevention, relief or treatment of women's climacteric or menopausal symptoms.

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

Modified relaxin polypeptides and their uses thereof are provided.

Provided is the composition capable of effectively exerting an effect on a change in a hormone balance. A composition for inhibiting the decrease in endogenous testosterone and/or dihydrotestosterone, the composition comprising Cordyceps militaris derived from Samia cynthia ricini and/or its extract is prepared.

[Problem] The purpose of the present invention is to provide a novel technology capable of regulating female hormone secretion. [Solution] Provided is an agent for regulating female hormone secretion, which contains the lactobacillus strain Lactobacillus gasseri strain CP2305 (accession No.: FERM PB-11331), a treated product of said lactobacillus strain, or extracts thereof.

The present invention discloses a substance for treating and/or preventing intolerance diseases and a design method and preparation method thereof. The stable structure corresponding to the substance related to the intolerance disease is used as the substance for treating and/or preventing the intolerance disease. The essence of disease is the imbalance of biological structure system. The imbalance of the structure of the substance in the biological structure system will cause diseases related to said substance. The present disclosure relates to the treatment and/or prevention of the intolerance disease by recognizing the stable structure corresponding to the substance by the body, adjusting the expression of its gene expression or genes by the self-adaptation, self-organization and other functions of body's structural system, and restoring the balance of the structure of the substance in the biological structure system.